reports
AMREP Reports Second Quarter Fiscal 2026 Results
AMREP Reports Second Quarter Fiscal 2026 Results HAVERTOWN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $1,200,000, or $0.22 per diluted share, for its 2026 fiscal second quarter ended October 31, 2025 compared to net income of $4,042,000, or $0.75 per diluted share, for the same period of the prior year. For the first six months of 2026, AMREP had net income of $5,892,000, or $1.09 per diluted share, compared to net income of $8,106,000, or $1.51 per diluted share, for the same period of 2025. Revenues were $9,398,000 and $27,250,000 f...
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financ...
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year endThese agreements ensure BioAtla can maintain operational momentum while completing that process SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the devel...
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Re...
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half ...
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrat...
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07...
- Jonathan Moreland
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
JBLU JETBLUE AIRWAYS CORPORATION
GBCI GLACIER BANCORP INC.
ASA ASA
TZOO TRAVELZOO
RLMD RELMADA THERAPEUTICS
NSC NORFOLK SOUTHERN CORPORATION
GCBC GREENE COUNTY BANCORP INC.
CSBR CHAMPIONS ONCOLOGY
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
CSBB C S B BANCORP OHIO
AVO MISSION PRODUCE
TDUP THREDUP INC.
NVCT NUVECTIS PHARMA INC
BPRN BANK OF PRINCETON
GTE GRAN TIERRA ENERGY INC.
BioAtla to Announce Third Quarter 2025 Financial Results and Provide B...
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference C...
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 w...
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase RO...
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA...
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for >6 monthsMaximally tolerated dose not yet defined; dose escalation continues; currently testing 1.8 mg dose level SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE...
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in So...
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 ...
AMREP Reports First Quarter Fiscal 2026 Results
AMREP Reports First Quarter Fiscal 2026 Results HAVERTOWN, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,692,000, or $0.87 per diluted share, for its 2026 fiscal first quarter ended July 31, 2025 compared to net income of $4,064,000, or $0.76 per diluted share, for the same period of the prior year. Revenues were $17,851,000 for the first quarter of 2026 and $19,091,000 for the first quarter of 2025. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which ...
BioAtla Announces Regulatory Update on Clinical Development Plan for O...
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next yearCompany maintains previous guidance for completion of a strategic partnership with one of our adva...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
ASYS AMTECH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
NWPP NEW PEOPLES BANKSHARES INC.
BHR BRAEMAR HOTELS & RESORTS
CCEL CRYO-CELL INTERNATIONAL
REZI RESIDEO TECHNOLOGIES
WU INC.
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
COO SELF STORAGE GROUP
REYN INC.
STTK PRECIGEN INC
ENOV THE COOPER COMPANIES INC.
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC SHATTUCK LABS
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
ISPO ENERGY TRANSFER LP
AFCG PRAIRIE OPERATING CO.
FG BAKKT HOLDINGS INC.
NIQ INSPIRATO INCORPORATED
STSS AFC GAMMA
FEAM INC.
SINT F AND G ANNUITIES AND LIFE
VWFB INC.
NIQ GLOBAL INTELLIGENCE PLC
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
VWF BANCORP
INC.
- Jonathan Moreland
BioAtla Reports Second Quarter 2025 Financial Results and Highlights R...
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management...
BioAtla to Announce Second Quarter 2025 Financial Results and Provide ...
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights. Conference Call and W...
AMREP Reports Fiscal 2025 Results
AMREP Reports Fiscal 2025 Results HAVERTOWN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $12,716,000, or $2.37 per diluted share, for its 2025 fiscal year ended April 30, 2025 compared to net income of $6,690,000, or $1.25 per diluted share, for the same period of the prior year. Revenues were $49,694,000 for fiscal 2025 and $51,369,000 for fiscal 2024. More information about the Company’s financial performance in 2025 and 2024 may be found in AMREP Corporation’s financial statements on Form 10-K which have today been filed with the Se...
BioAtla Announces Upcoming Oral Presentation at the 2025 European Soci...
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced an oral presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting to be held in Hong Kong Sar, China from July 18–20, 2025. Oral Presentation Details...
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Con...
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing SAN DIEGO, July 03, 2025 (GLOBE NE...
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PZG PARAMOUNT GOLD NEVADA CORP.
IRIX IRIDEX CORP.
VFF VILLAGE FARMS INTERNATIONAL IN
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
GRF ASTRONOVA INC.
NHF EAGLE CAPITAL GROWTH FUND INC
BCBP NEXPOINT CREDIT STRATEGIES FUN
RSSS BCB BANCORP INC.
NWPP RESEARCH SOLUTIONS
RFL NEW PEOPLES BANKSHARES INC.
ULBI RAFAEL HOLDINGS CL B
YMAB ULTRALIFE
IMUX Y-MABS THERAPEUTICS
AMPY IMMUNIC INC
INLX AMPLIFY ENERGY
ENX INTELLINETICS
DLHC INC.
COOK EATON VANCE NEW YORK MUNICIPAL BOND FUND
IMRX DALEIGH HOLDINGS CORP
XLO TRAEGER
NVCT INC.
GECC IMMUNEERING CORP
BARK XILIO THERAPEUTICS INC
NNUP NUVECTIS PHARMA INC
ERNA GREAT ELM CAPITAL CORP
GTE ORIGINAL BARK CO
GENK NOCOPI TECHS INC
SRBK ETERNA THERAPEUTICS INC.
NKGN GRAN TIERRA ENERGY INC.
PROP GEN RESTAURANT GROUP INC
ACTU SR BANCORP INC
SUNS NKGEN BIOTECH INC
EVM PRAIRIE OPERATING CO.
MBRX ACTUATE THERAPEUTICS INC.
SLS SUNRISE REALTY TRUST
WHLR EATON VANCE INSD CALIF MUN BD FD
HYMC MOLECULIN BIOTECH INC.
THAR SELLAS LIFE SCIENCES GROUP INC
RVYL WHEELER REAL ESTATE INVESTMENT TRUST INC.
INUV HYCROFT MINING HOLDING CORPORATION
CCIF THARIMMUNE INC.
RYVYL INC.
INUVO INC.
CARLYLE CREDIT INCOME FUND
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
FFIN FIRST FINANCIAL BANKSHARES INC
CAL CALERES INC.
CABO CABLE ONE INC.
PATK PATRICK INDUSTRIES INC.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
CC CHEMOURS CO.
IOVA IOVANCE BIOTHERAPEUTICS INC
QTRX QUANTERIX CORPORATION
RSSS RESEARCH SOLUTIONS
BHC BAUSCH HEALTH COMPANIES INC.
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
ETON ETON PHARMACEUTICALS
IMUX IMMUNIC INC
BLDR BUILDERS FIRSTSOURCE
FNWB INC.
AMPY FIRST NORTHWEST BANCORP
DCTH AMPLIFY ENERGY
ENX DELCATH SYSTEMS
TSHA EATON VANCE NEW YORK MUNICIPAL BOND FUND
SMMT TAYSHA GENE THERAPIES
HLMN SUMMIT THERAPEUTICS INC
COOK HILLMAN SOLUTIONS CORP.
AIRS TRAEGER
GECC INC.
TYRA AIRSCULPT TECHNOLOGIES INC
NNUP GREAT ELM CAPITAL CORP
BHRB TYRA BIOSCIENCES INC
DPG NOCOPI TECHS INC
RNXT BURKE & HERBERT BANK & TR/VA
GTE DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK RENOVORX INC
NKGN GRAN TIERRA ENERGY INC.
MNR SR BANCORP INC
NBBK NKGEN BIOTECH INC
NCDL MACH NATURAL RESOURCES LP
SDHY NB BANCORP INC.
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
WHLR PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
ABACUS GLOBAL MANAGEMENT INC.
WHEELER REAL ESTATE INVESTMENT TRUST INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.